Ici 182,780 (fulvestrant ™) – the first oestrogen receptor down-regulator – current clinical data

ABSTRACT ICI 182,780 (Fulvestrant™) is the first in a new class of novel, steroidal, ’pure‘ antioestrogens – the oestrogen receptor (ER) down-regulators. Its unique mode of action and the

absence of partial agonist activity make it a candidate for the treatment of advanced breast cancer in both pre- and postmenopausal women. Tamoxifen has been available for use over the past

25 years. However, its partial agonist activity has been associated with detrimental effects, particularly on the endometrium, and may be associated with the development of tamoxifen

resistance. Other antioestrogen agents have previously been unable to demonstrate clinically relevant activity following the development of resistance to tamoxifen. In contrast, the unique

mechanism of action of ICI 182,780 results in significant clinical activity in patients failing on tamoxifen therapy. Indeed, phase III clinical trials have demonstrated that ICI 182,780 is

at least as effective as the aromatase inhibitor anastrozole in the treatment of postmenopausal patients with advanced disease who have progressed during threatment with prior enocrine

therapy. As such, ICI 182,780 will provide a valuable addition to the armamentarium for the treatment of advanced breast cancer. © 2001 Cancer Research Society SIMILAR CONTENT BEING VIEWED

BY OTHERS ELACESTRANT DEMONSTRATES STRONG ANTI-ESTROGENIC ACTIVITY IN PDX MODELS OF ESTROGEN-RECEPTOR POSITIVE ENDOCRINE-RESISTANT AND FULVESTRANT-RESISTANT BREAST CANCER Article Open access

29 November 2022 AMEERA-1 PHASE 1/2 STUDY OF AMCENESTRANT, SAR439859, IN POSTMENOPAUSAL WOMEN WITH ER-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER Article Open access 15 July 2022

FULVESTRANT PLUS VANDETANIB VERSUS PLACEBO FOR THE TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY (FURVA): A MULTICENTRE, PHASE 2, RANDOMISED

CONTROLLED TRIAL Article Open access 14 September 2023 ARTICLE PDF CHANGE HISTORY * _ 16 NOVEMBER 2011 This paper was modified 12 months after initial publication to switch to Creative

Commons licence terms, as noted at publication _ AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Surgery, City Hospital Nottingham, Nottingham, NG5 IPB, UK J F R Robertson

Authors * J F R Robertson View author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS From twelve months after its original publication, this

work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit

http://creativecommons.org/licenses/by-nc-sa/3.0/ Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Robertson, J. ICI 182,780 (Fulvestrant ™) – the first oestrogen receptor

down-regulator – current clinical data. _Br J Cancer_ 85 (Suppl 2), 11–14 (2001). https://doi.org/10.1054/bjoc.2001.1982 Download citation * Published: 30 November 2001 * Issue Date: 01

November 2001 * DOI: https://doi.org/10.1054/bjoc.2001.1982 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a

shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * ICI 182,780 * anastrozole *

tamoxifen * antioestrogens * advanced breast cancer * adjuvant therapy